Depression in Parkinson's disease: the effectiveness and risk of pharmacotherapy. Clinical review.

Parkinson's disease (PD) is a neurological disease with a heterogeneous pattern of neurological symptoms and concomitant psychiatric syndromes. These syndromes are triggered by alterations to neurotransmission that are likely common for both neurological and psychiatric symptoms. Syndromes such as depression, anxiety, or cognitive impairment can precede motor symptoms of PD and delay its diagnosis.

RANKL/RANK/OPG system and bone status in females with anorexia nervosa.

Minimal data exist concerning the relationship between osteokines of the RANKL/RANK/OPG system, especially RANKL, and bone status in females with anorexia nervosa (AN). For this reason we investigated the relationship between bone metabolism (as assessed based on serum levels of OC and CTx), and OPG and sRANKL concentrations in females with AN. Ninety-one female patients with AN and 29 healthy female subjects aged 13 to 18 years of age participated in the study.

Bupropion in the treatment of depression in Parkinson's disease.

A 78-year-old female with a nine-year history of depression was hospitalized due to worsening depression and symptoms associated with Parkinson's disease (PD). Her motor abilities improved on levodopa and the depression improved after a trial of bupropion, following unsuccessful treatment with other antidepressants. We found four reports on successful treatment of depression in PD with bupropion.

Assessment of serum apelin levels in girls with anorexia nervosa.

Context: Pilot studies in rats have suggested that apelin (APE) is involved in the control of appetite and food intake. APE is secreted in the organs involved in the control of hunger and satiety: the stomach, hypothalamus, and fat tissue. Anorexia nervosa (AN) is an eating disorder that represents a good biological model of chronic fat tissue atrophy in humans.

Melatonin, the RANKL/RANK/OPG system, and bone metabolism in girls with anorexia nervosa.

Introduction: Young women and girls with anorexia nervosa (AN) suffer from abnormalities in melatonin (MEL) secretion, especially in the nocturnal phase. This is paralleled by a considerable bone mass loss and abnormalities of bone metabolism. As melatonin has been implicated in playing a role in inducing osteoporosis and that the effect could be mediated by the RANKL/RANK/OPG system, we decided to investigate the potential associations between MEL and bone status in girls with AN.